C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer
A biomarker is a biological molecule found in blood, other body [...]
Telaglenastat plus cabozantinib in patients with metastatic kidney cancer
Cell metabolism in kidney cancer tumours is disrupted, and tumour [...]
ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer
The phase 2 KEYNOTE-B61 study was presented at the recent [...]
ESMO 2022: Update of the lenvatinib plus pembrolizumab versus sunitinib study in patients with advanced kidney cancer
Results from the phase 3 CLEAR studywere presented at the [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab
Neutrophils and eosinophils are white blood cells. In this study, [...]
Nivolumab plus ipilimumab for localised kidney cancer
In a recent phase 3 clinical trial the combination of [...]
Adjuvant nivolumab plus ipilimumab for kidney cancer
Adjuvant therapy is medication that is given after surgery to [...]
Health-related quality of life with lenvatinib in combination with everolimus
Maintaining good health-related quality of life is important for all [...]
Cabozantinib plus nivolumab and ipilimumab delays progression in kidney cancer
Preliminary results from the COSMIC-313 clinical trial have ben released. [...]
